Harold Nathan Tan, MD, MBA, MS
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Thoracic-Head & Neck Med Onc, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2021 | University of the Philippines Manila, Manila, National Capital Region, PH, Medical Oncology, Master of Science in Clinical Medicine |
| 2014 | Ateneo School of Medicine and Public Health, Doctor of Medicine |
| 2014 | Ateneo School of Medicine and Public Health, Master’s in Business Administration |
Postgraduate Training
| 2025-2025 | Trainee, Leading Clinical Research Faculty Learning Series, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2024-2026 | Clinical Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2022-2024 | Clinical Research Fellow, NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, England |
Licenses & Certifications
| 2026 | Texas Temporary Faculty License |
| 2026 | Basic Life Support, American Heart Association |
| 2026 | Advanced Cardiac Life Support, American Heart Association |
| 2024 | Texas Physician-in-Training Permit |
| 2024 | Associate Principal Investigator Certification, National Institute for Health and Care Research and The Royal College of Physicians |
| 2023 | United States Educational Commission for Foreign Medical Graduates Certification |
| 2022 | Certificate of Full Registration as a Medical Practitioner, General Medical Council, United Kingdom |
| 2021 | Medical Oncology Board Certification, Philippine Society of Medical Oncology |
| 2019 | Internal Medicine Board Certification, Philippine College of Physicians |
| 2014 | Physician License, Professional Regulation Commission Philippines |
Experience & Service
Administrative Appointments/Responsibilities
Associate Chief Fellow for Research,, Department of Medicine,, University of the Philippines – Philippine General Hospital, 2020 - 2021
Honors & Awards
| 2025 - Present | Methods in Clinical Cancer Research Workshop, ASCO/AACR |
| 2024 - 2025 | ASCO JCO Journals Editorial Fellowship Awardee |
| 2022 - Present | Rising Stars in Asia Workshop Awardee, Japanese Society of Medical Oncology |
| 2022 - Present | Global Health Award Recipient, Keystone Symposia On Molecular and Cellular Biology |
| 2022 - Present | International Development and Education (IDEA) Awardee, ASCO |
| 2021 - Present | Graduate University Merit Scholar, University of the Philippines |
| 2021 - Present | Dr. Clemente Gatmaitan Award for Most Outstanding Fellow in Research, University of the Philippines – Philippine General Hospital Department of Medicine |
| 2020 - Present | Drs. Reuben and Celina Guerrero Annual Cancer Research Forum Contest, Meta-Analysis Category |
| 2020 - Present | Virtual Fellowship Awardee, UICC |
| 2020 - Present | Virtual Mentorship Programme Awardee, ESMO |
| 2020 - Present | World GI Congress Merit Awardee, ESMO |
| 2020 - Present | Drs. Reuben and Celina Guerrero Annual Cancer Research Forum Contest , Analytic Category |
| 2020 - Present | Philippine General Hospital Annual Research Paper Contest, Meta-Analysis Category, University of the Philippines |
| 2020 - Present | Philippine General Hospital Department of Medicine Annual Research Forum, Original Study Category, University of the Philippines |
| 2020 - 2021 | Virtual Mentoring Program Awardee, ASCO |
| 2019 - Present | Immuno-Oncology Congress Merit Awardee, ESMO |
| 2019 - Present | Dr. Reuben C. Guerrero Annual Cancer Research Forum Contest, Meta- Analysis Categoryy |
| 2019 - Present | Dr. Reuben C. Guerrero Annual Cancer Research Forum Contest, Case Report Category |
| 2018 - Present | Most Outstanding Resident in Internal Medicine, Makati Medical Center |
| 2018 - Present | Dr. Reuben C. Guerrero Annual Cancer Research Forum Paper Contest, Analytical Study Category |
| 2018 - Present | Excellence in Research Award, Makati Medical Center |
| 2017 - Present | Most Outstanding Resident in Internal Medicine, Makati Medical Center |
| 2016 - Present | 15th Annual Medicine House Staff Scientific Presentation: Case Report Category, Makati Medical Center |
| 2016 - Present | Most Outstanding Resident in Internal Medicine, Makati Medical Center |
| The 19th Annual Meeting Travel Awardee, JSMO | |
| 17th Annual Medicine House Staff Scientific Presentation: Original Research Category, Makati Medical Center |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Beyond the Checkpoint: Novel Immunotherapy Agents and Combinations in Head and Neck Cancer. Conference. Houston, Texas, US.
- 2025. Updates from ASCO 2025. Conference. Grand Rounds. Houston, Texas, US.
- 2025. Depression and Cancer, Department of Investigational Cancer Therapeutics Journal Club. Conference. Houston, Texas, US.
- 2025. Grand Rounds, Mortality and Morbidity Conference. Conference. Houston, Texas, US.
- 2024. Journal Club Targeting the Lymph Nodes to Amplify the Immune Response. Conference. Houston, Texas, US.
National Presentations
- 2025. Novel immunotherapy agents and combinations in early phase trials for head and neck cancer. Conference. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. San Diego, California, US.
- 2025. Defining clinical and molecular determinants of treatment benefit and survival in early phase immunotherapy trials. Conference. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. San Diego, California, US.
- 2025. Association of Immune-Related Adverse Events with Survival and Treatment Outcomes in Thymic Tumors Treated with Immune Checkpoint Inhibitors. Conference. 2025 ASCO Annual Meeting. Chicago, Illinois, US.
- 2024. Adverse events of patients treated with antibody-drug conjugates in phase 1 clinical trials at the Royal Marsden Drug Development Unit from 2014 to 2024. Conference. 2024 ASCO Annual Meeting. Chicago, Illinois, US.
International Presentations
- 2025. Immune Complex Profiling Identifies Biomarkers of Response to Immune Checkpoint Inhibitors Across Cancers. Conference. ESMO Immuno-Oncology Congress. Hamburg, DE.
- 2025. Phase I study of NovoTTF-100L(P) in combination with chemotherapy in patients with predominant hepatic metastatic. Conference. ESMO Congress 2025. Berlin, DE.
- 2025. A phase 1 dose escalation and dose expansion trial of NP-101 in patients with advanced solid tumors. Conference. ESMO Congress 2025. Berlin, DE.
- 2025. A Phase I trial of Tepotinib and Pembrolizumab in Non-Small Cell Lung Cancer (NSCLC). Conference. 2025 European Lung Cancer Congress. Paris, France. Paris, FR.
Selected Publications
Peer-Reviewed Articles
- Tan HN, Mandayam S, Roy-Chaudhury P, Yap TA. Modernizing renal eligibility in oncology trials. Lancet Reg Health Am 62:101575, 2026. e-Pub 2026. PMID: 42569667.
- Tan HN, Stephen B, Mirallas O, Derbala MH, Salih I, Castillo L, Yang Y, Le H, Kang L, Lin H, Lim J, Dumbrava EE, Yap TA, Rodon J, Piha-Paul SA, Fu S, Champiat S, Akhave N, Ferrarotto R, Hong DS, Meric-Bernstam F, Johnson F, Naing A. Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer. JAMA Netw Open 9(7):e2623522, 2026. e-Pub 2026. PMID: 42461627.
- Tan HN, Le H, Frej KBH, Kang L, Champiat S, Meric-Bernstam F, Fossella F, Naing A, Sharon E, Altan M, Dumbrava EE. Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors. NPJ Precis Oncol, 2026. e-Pub 2026. PMID: 42286316.
- Torrado C, Andersen CR, Kang L, Brink AL, Adesoye T, Le H, Patterson CJ, Poullard A, Osburn JA, Tan HN, Gouda MA, Charles S, Urschel GE, Tang TY, Hong DS, Champiat S, Naing A, Tsimberidou AM, Dumbrava EE, Piha-Paul SA, Rodon J, Yap TA, Pohlmann PR, Meric-Bernstam F, Fu S. Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity. Oncologist 31(4), 2026. e-Pub 2026. PMID: 41830429.
- Tan HN, Morcillo MA, Lopez J, Minchom A, Sharp A, Paschalis A, Silva-Fortes G, Raobaikady B, Banerji U. Treatment-related adverse events of antibody drug-conjugates in clinical trials. J Hematol Oncol 18(1):71, 2025. e-Pub 2025. PMID: 40611310.
- Velasco RN Jr, Ando MM, Javelosa MAU, King REC, Mondragon KAM, Tan HNC, Ngelangel CA, Real IO, et al.. The Magnitude of Delay in Non-metastatic Breast Cancer Treatment in a Tertiary Hospital: an Analysis from 2012 to 2018. Acta Med Philipp 59(8):45-51, 2025. e-Pub 2025. PMID: 40755562.
- Tan HN, Ben Haj Frej K, Kang L, et al.. Association of immune-related adverse events with survival and treatment outcomes in thymic tumors treated with immune checkpoint inhibitors. JCO(43(16_suppl):8111-8111), 2025. e-Pub 2025.
- Tan HN, Catedral LIG, Velasco RJ, San Juan M. Receptor conversion and vocal cord paralysis in a patient with breast cancer. BMJ Case Rep 15(2), 2022. e-Pub 2022. PMID: 35140078.
- Tan HN, Velasco RN, Catedral LIG, San Juan MD, Ngelangel C, Calvo E. The experience of pain among cancer patients at the University of the Philippines: Philippine General Hospital Cancer Institute—A cross-sectional study. JCO(39(15_suppl):e24078-e24078), 2021. e-Pub 2021.
- Catedral LI, Tan HN, Chua A Jr, Benedict Sacdalan D, Sacdalan DL. Patterns of Biomarker Use in Cancer Treatment Among Medical Oncologists in the Philippines. JCO Glob Oncol 6:1593-1608, 2020. e-Pub 2020. PMID: 33079606.
- Tan HN, Velasco RN, San Juan MD, Cornelio GH. Cytokines as a prognostic biomarker of overall survival in pancreatic cancer. JCO(38(15_suppl):e16753-e16753), 2020. e-Pub 2020.
- Mendoza MJL, Tan HNC, Hernandez ARB, Dala BCA, Sacdalan DBL, Sacdalan DL, Cornelio GH, Ignacio JG. Medical oncology care amidst the COVID-19 pandemic at the National University Hospital in the Philippines. Ecancermedicalscience 14:1066, 2020. e-Pub 2020. PMID: 32728382.
- Tan HN, Rodriguez CC, Monte KA, Tan PG, Cornelio GDH. Immune checkpoint proteins as a prognostic biomarker of overall survival in non-small cell lung cancer. Annals of Oncology(31:S283), 2020. e-Pub 2020.
- Catedral LIG, Caro-Chang LA, Tan HN, Velasco R, King RE, Ting FI, et al.. AIDS-Related Kaposi Sarcoma in a Tertiary University Hospital in Manila, Philippines: A Report of Six Cases. Asian Journal of Oncology(Sep 07(03)):144-6, 2020. e-Pub 2020.
Review Articles
- Mirallas O, Pretelli G, Balsa M, Jimenez-Labaig P, Hernando-Calvo A, Nathan Tan H, Selvadurai PN, Tallon de Lara P, Vieito M, Martin-Liberal J, Harrington KJ, Champiat S, Garralda E. Targeting regulatory T cells for cancer immunotherapy: promises and pitfalls. Ann Oncol 37(8):1049-1065, 2026. e-Pub 2026. PMID: 42066959.
- Tan HN, Curigliano G, Yap TA. Targeting cyclin-dependent kinases in cancer: emerging therapeutics and clinical strategies. Trends Cancer 12(6):553-568, 2026. e-Pub 2026. PMID: 42020210.
- Coleman N, Tan HN, Rodon Ahnert J. Progress in targeting the untouchables: emerging approaches for hard-to-drug cancer targets. Ann Oncol 37(5):624-638, 2026. e-Pub 2026. PMID: 41638486.
- Tan HN, Elliott MJ, Silverman IM, Siu LL, Yap TA. Circulating tumor DNA as a biomarker in early phase clinical trials. Cancer Cell 44(2):240-247, 2026. e-Pub 2026. PMID: 41418771.
- Torrado C, Gonzalez-Ortiz A, Xavier CB, Tan HN, Ngoi NYL, Yap TA. Drugging the DNA damage response in the clinic: going beyond PARP. Expert Rev Anticancer Ther 26(1):43-58, 2026. e-Pub 2026. PMID: 41086259.
- Velasco RN Jr, Tan HNC, Juan MDS. Haematologic biomarkers and survival in gallbladder cancer: a systematic review and meta-analysis. Ecancermedicalscience 18:1660, 2024. e-Pub 2024. PMID: 38425767.
Other Articles
- Tan HNC, Catedral LIG, San Juan MD Prognostic Significance of Tumor-infiltrating Lymphocytes on Survival Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. J Immunother 44(1):29-40, 2021. PMID: 32909965.
- Tan HN, Velasco RN, Catedral LI 1718P Quality of life of patients with cancer and their family caregivers at the University of the Philippines – Philippine General Hospital Cancer Institute using the WHO Quality of Life-BREF Filipino. Annals of Oncology(32:S1193), 2021.
- Tan, Tamayo, Rosales, et al. A Retrospective Cohort Study on the Disease-Free Survival and Overall Survival of Patients with Stage I-III Triple Negative Breast Cancer Given Adjuvant Chemotherapy in Makati Medical Center, Philippines. Phil Journal of Internal Medicine(59(3)):196-204, 2021.
- Tan, H, Rodon J, Dumbrava E, et al. Phase I Study of NovoTTF-100L(P) in Combination with Chemotherapy in Patients with Predominant Hepatic Metastatic Colorectal Cancer. ESMO Open.
- Tan HN, Stephen B, Hong Leung C, et al. Defining clinical and molecular determinants of benefit in early phase immunotherapy trials. JAMA Oncology.
- Torrado C, Andersen CR, Tan HN, et al. Shaping the future of patient evaluation for clinical trials via telemedicine: The MD Anderson Phase 1 Program experience, 2016–2023. Cancer Communications.
- Moyers J, Nguyen D, Tan HN, et al. Adherence to the Food and Drug Administration (FDA) guidance for the co-development of two or more investigational new drugs in phase 1/2 cancer trials. Clinical Cancer Research.
- Tan, HN, Mandayam, SA, Roy-Chaudhury, P, Yap, T Modernizing renal eligibility in oncology trials. Lancet Regional Health. Americas:62.
- Tan HN, Brown, Oliva-Rico, al D Copaful: Phase 2 study of PI3K inhibitor copanlisib in combination with fulvestrant in selected ER+ and/or PR+ cancers with PI3K (PIK3CA, PIK3R1) and/or PTEN alterations. JCO.
Book Chapters
- Torrado C, Tan HN, Yap TA. Targeting DNA damage response pathways in cancer. In: Comprehensive Medicinal Chemistry. 4th. Elsevier, 2025.
- Tan HN, Rodon L, Rodon J. Small molecules: Nonkinase inhibitors. In: Handbook of Precision Oncology. 1st. Wolters Kluwer, 2025.
Patient Reviews
CV information above last modified September 29, 2026